MESENCHYMAL STEM CELLS AND USES THEREFOR

• US 20090208463A1
• Filed: 09/26/2007
• Published: 08/20/2009
• Est. Priority Date: 03/22/2004
• Status: Abandoned Application

• Current Assignee: Mesoblast International Srl
• Original Assignee: Mesoblast International Srl
• Inventors: Varney, Timothy, Aggarwal, Sudeepta, Pittenger, Mark F.
• Application Number:
  US12/091,387
• Publication Number:
  US 20090208463A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/2026 IL-4
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 5/0662 : Stem cells
• CPC Class Codes: C12N 5/0663 : Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0664 : Dental pulp stem cells, Dental follicle stem cells
• CPC Class Codes: C12N 5/0665 : Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0666 : Mesenchymal stem cells from hair follicles
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Claims

1. A method of promoting angiogenesis in an organ or tissue of an animal other than the heart, comprising:

administering to said animal mesenchymal stem cells in an amount effective to promote angiogenesis in an organ or tissue other than the heart of said animal.

2. The method of claim 1 wherein said animal is a mammal.

3. The method of claim 2 wherein said mammal is a primate.

4. The method of claim 3 wherein said primate is a human.

5. The method of claim 1 wherein said mesenchymal stem cells are administered in an amount of from about 1×

10⁵ cells/kg to about 1×

10⁷ cells/kg.

6. The method of claim 5 wherein said mesenchymal stem cells are administered in an amount of from about 1×

10⁶ cells/kg to about 5×

10⁶ cells/kg.

7. The method of claim 1 wherein said mesenchymal stem cells are administered systemically.

8. The method of claim 1 wherein said mesenchymal stem cells are administered intravenously.

9. The method of claim 1 wherein said mesenchymal stem cells are administered by direct injection to said organ or tissue other than the heart of said animal.

10. A method of treating a disease selected from the group consisting of autoimmune diseases and graft-versus-host in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said disease in said animal

11. The method of claim 10 wherein said animal is a mammal

12. The method of claim 11 wherein said mammal is a human.

13. The method of claim 10 wherein said disease is multiple sclerosis.

14. A method of treating an inflammatory response in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said inflammatory response in said animal.

15. The method of claim 14 wherein said animal is a mammal.

16. The method of claim 15 wherein said mammal is a human.

17. The method of claim 14 wherein said inflammatory response is associated with psoriasis.

24. The method of claim 14 wherein said allergic disease or disorder is arthritis.

18. A method of treating cancer in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat cancer in said animal.

19. The method of claim 18 wherein said animal is a mammal.

20. The method of claim 19 wherein said mammal is a human.

21. A method of treating an allergic disease or disorder in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said allergic disease or disorder in said animal.

22. The method of claim 21 wherein said animal is a mammal.

23. The method of claim 22 wherein said mammal is a human.

25. A method of promoting wound healing in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to promote wound healing in said animal.

26. The method of claim 25 wherein said animal is a mammal.

27. The method of claim 26 wherein said mammal is a human.

28. A method of preventing fibrosis in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to prevent fibrosis in said animal.

29. A method of repairing epithelial damage in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to repair epithelial damage in said animal.

30. The method of claim 29 wherein said animal is a mammal.

31. The method of claim 30 wherein said mammal is a human.

32. The method of claim 29 wherein said epithelial damage is a result of graft-versus-host disease.